作者
Yasuhito Hamaguchi,Masataka Kuwana,Kana Hoshino,Minoru Hasegawa,Kenzo Kaji,Takashi Matsushita,Kazuhiro Komura,Motonobu Nakamura,Masanari Kodera,Norihiro Suga,Akira Higashi,Koji Ogusu,Kiyohiro Tsutsui,Akira Furusaki,Hiroshi Tanabe,Shunsuke Sasaoka,Yoshinao Muro,Mika Yoshikawa,Naoko Ishiguro,Masahiro Ayano,Eiji Muroi,Keita Fujikawa,Yukihiro Umeda,Masaaki Kawase,Eriko Mabuchi,Yoshihide Asano,Kinuyo Sodemoto,Mariko Seishima,Hidehiro Yamada,Shinichi Sato,Kazuhiko Takehara,Manabu Fujimoto
摘要
To clarify the association of clinical and prognostic features with dermatomyositis (DM)-specific autoantibodies (Abs) in adult Japanese patients with DM.Retrospective study.Kanazawa University Graduate School of Medical Science Department of Dermatology and collaborating medical centers. Patients A total of 376 consecutive adult Japanese patients with DM who visited our hospital or collaborating medical centers between 2003 and 2008.Clinical and laboratory characteristics of adult Japanese patients with DM and DM-specific Abs that include Abs against Mi-2, 155/140, and CADM-140.In patients with DM, anti-Mi-2, anti-155/140, and anti-CADM-140 were detected in 9 (2%), 25 (7%), and 43 (11%), respectively. These DM-specific Abs were mutually exclusive and were detected in none of 34 patients with polymyositis, 326 with systemic sclerosis, and 97 with systemic lupus erythematosus. Anti-Mi-2 was associated with classical DM without interstitial lung disease or malignancy, whereas anti-155/140 was associated with malignancy. Patients with anti-CADM-140 frequently had clinically amyopathic DM and rapidly progressive interstitial lung disease. Cumulative survival rates were more favorable in patients with anti-Mi-2 compared with those with anti-155/140 or anti-CADM-140 (P < .01 for both comparisons). Nearly all deaths occurred within 1 year after diagnosis in patients with anti-CADM-140. Conclusion Dermatomyositis-specific Abs define clinically distinct subsets and are useful for predicting clinical outcomes in patients with DM.